Comera Life Sciences: Study Reinforces Caffeine’s Viscosity-Reducing Capabilities

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) announces the publication of preclinical data in the Journal of Pharmaceutical Sciences, demonstrating caffeine’s viscosity-reducing capabilities and supporting further development of caffeine as a viscosity reducing agent for subcutaneous (SQ) formulations of monoclonal antibodies.

Comera’s studies assessed the pharmacokinetic (PK) characteristics of caffeine and its influence on the PK behavior of a representative monoclonal antibody (mAb) ipilimumab.

Jeffrey Hackman, Chairman and Chief Executive Officer of Comera, said, “These insights bring us closer to delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines. We look forward to continuing the development of caffeine as a viscosity reducing agent for subcutaneous monoclonal antibody formulations, while also embarking on the expansion of our computational modeling tools to potentially include cutting-edge AI capabilities.”


Comera’s preclinical studies showed rapid SQ absorption and elimination of caffeine, regardless of whether it was administered alone or in conjunction with the monoclonal antibody.

Caffeine exhibited no impact on the PK profiles of ipilimumab with SQ administration.

No adverse effects were observed at the injection site.

Robert Mahoney, Ph.D., Chief Scientific Officer of Comera, said, “This study is an important validation of caffeine’s potential to address critical viscosity challenges in developing subcutaneous biologics. The results further support the rapid dissociation of caffeine upon subcutaneous injection and that caffeine does not affect pharmacokinetic profiles of the model monoclonal antibody, both of which are critical features of a successful subcutaneous formulation.”

The publication titled, “Preclinical Pharmacokinetic Study on Caffeine as an Excipient for Monoclonal Antibody Formulations,” can be accessed here.

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.

To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit

Share This Article


About the Author

Comera Life Sciences: Study Reinforces Caffeine’s Viscosity-Reducing Capabilities

Editor Prism MarketView